Compound Reference
Short review of three GLP-1-class peptides: receptor pharmacology, SURPASS-2, and published retatrutide trials. Research use only. Not for human consumption.
August 29, 2026
No Comments
Short review of three GLP-1-class peptides: receptor pharmacology, SURPASS-2, and published retatrutide trials. Research use only. Not for human consumption.
No head-to-head trial has been published. TRIUMPH-5 is running and reads out late 2026. Here is what each molecule is, and why the usual comparison
The field has not settled whether the GIP receptor should be switched on or off — both produce weight loss in animals. What each receptor
No trial of retatrutide versus semaglutide exists — published or registered. Here is what can honestly be compared, and why the numbers you have seen
Two randomised head-to-head trials exist. Tirzepatide led on weight and HbA1c; semaglutide holds the cardiovascular outcomes data. Both results, with confidence intervals.
Retatrutide is a triple agonist, but not an equal one. It is roughly 8.9x more potent at GIPR than native GIP and weaker at the
No. We queried Drugs@FDA directly and it returns zero records. Here is the sourced answer, plus why a DailyMed listing is not an approval.
GLOW vs KLOW: What Separates These Two Research Blends If you’ve spent any time in the peptide research space, you’ve seen the same four or